TABLE 1.
Demographic and Clinical Variables of 3 Scenarios for Switching Tacrolimus Formulations
| Variable | Scenario; No. (%) of Episodes or Mean ± SD | ||
|---|---|---|---|
|
| |||
| IV to Oral Suspension (n = 8) | IV to Capsule (n = 14) | Oral Suspension to Capsule (n = 19) | |
| Sex, female | 3 (38) | 5 (36) | 5 (26) |
|
| |||
| Age (years) | 56.4 ± 9.0 | 54.5 ± 12.6 | 50.2 ± 12.0 |
|
| |||
| Weight (kg) | 77 ± 14.1 | 79.2 ± 15.6 | 78.25 ± 20.2 |
|
| |||
| Time since transplanta (months) | 39.4 ± 108.4 | 6.3 ± 8.2 | 22.9 ± 53.6 |
|
| |||
| Enteral feeding | 8 (100) | 7 (50) | 16 (84) |
|
| |||
| Recent surgeryb | 8 (100) | 8 (57) | 10 (53) |
|
| |||
| Type of transplanted organ | |||
| Heart | 7 (88) | 12 (86) | 17 (89) |
| Kidney | 1 (12) | 1 (7) | 1 (5) |
| Lung | 0 (0) | 1 (7) | 1 (5) |
|
| |||
| Interacting drugs | |||
| Azoles | 1 (12) | 0 (0) | 4 (21) |
| Corticosteroid | 8 (100) | 12 (86) | 18 (95) |
| Dose 7 days before switch (mg) | 53.8 ± 25.9 | 161.2 ± 335.7 | 39.7 ± 54.3 |
| Dose on day of switch (mg) | 42.2 ± 18.3 | 29.5 ± 20.5 | 22.1 ± 12.1 |
| Dose 5 days after switch (mg) | 37.7 ± 25.1 | 22.7 ± 15.1 | 20.9 ± 11.1 |
|
| |||
| Clinical lab results before switch | |||
| ALT (IU/L) | 87.3 ± 101.6 | 63.3 ± 85.2 | 44 ± 57.7 |
| eGFR (mL/min/1.73 m2) | 61.8 ± 31.4 | 59.1 ± 33.6 | 57.6 ± 35.1 |
| Hematocrit | 0.311 ± 0.053 | 0.272 ± 0.033 | 0.283 ± 0.044 |
| Albumin (g/L) | 33.8 ± 8.7 | 32.8 ± 4.4 | 30.9 ± 4.4 |
|
| |||
| Clinical lab results after switch | |||
| ALT (IU/L) | 71.8 ± 89.4 | 40.1 ± 24.1 | 62.5 ± 112.3 |
| eGFR (mL/min/1.73 m2) | 49.9 ± 36.5 | 53.4 ± 27.2 | 55.9 ± 35.8 |
| Hematocrit | 0.266 ± 0.014 | 0.273 ± 0.055 | 0.263 ± 0.021 |
| Albumin (g/L) | 28.7 ± 6.4 | 32.7 ± 3.8 | 29.8 ± 5.0 |
ALT = alanine aminotransferase, eGFR = estimated glomerular filtration rate, SD = standard deviation.
a
Time since transplant at the moment of switch in formulation.
b
Surgery of any type that occurred within 30 days of the switch in formulation.